Loading...
BEAM Beam Therapeutics
No Data
News
Comment
The past year for Beam Therapeutics (NASDAQ:BEAM) investors has not been profitable
Investing in stocks comes with the risk that the share price will fall. Unfortunately, shareholders of Beam Therapeutics Inc. (NASDAQ:BEAM) have suffered share price declines over the last year. Th
Covid-19 Windfalls Might Accelerate Pharma M&A -- Market Insight
Commentary by Adria Calatayud Pfizer is deploying part of its cash pile from Covid-19 vaccine and antiviral drug sales in the acquisition of Biohaven Pharmaceutical Holding shares it doesn't a
Beam Therapeutics (BEAM) Gets a Hold Rating from RBC Capital
RBC Capital analyst Luca Issi maintained a Hold rating on Beam Therapeutics (BEAM – Research Report) on May 9 and set a price target of $85.00. The company's shares closed last Tuesday at $35.78, clo
Barclays Keeps a Hold Rating on Beam Therapeutics (BEAM)
Barclays analyst Gena Wang maintained a Hold rating on Beam Therapeutics (BEAM – Research Report) on May 9 and set a price target of $38.00. The company's shares closed last Tuesday at $35.78, close
Beam Therapeutics (BEAM) Receives a Hold from J.P. Morgan
In a report released yesterday, Eric Joseph from J.P. Morgan maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target of $102.00. The company's shares closed last M
Wedbush Cuts Beam Therapeutics' Price Target to $100 From $152, Citing Liver Programs Timeline, Lowered Ramp for BEAM-101; Outperform Rating Kept
04:44 AM EDT, 05/10/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Beam Therapeutics Is Maintained at Outperform by SVB Leerink
Beam Therapeutics Is Maintained at Outperform by SVB Leerink
Beam Therapeutics Price Target Raised to $121.00/Share From $118.00 by SVB Leerink
Beam Therapeutics Price Target Raised to $121.00/Share From $118.00 by SVB Leerink
Beam Therapeutics analyst ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2022 250.22% SVB Leerink $118 → $121 Maintains Outperform 04/28/2022 79.45% Credit Suisse → $62 Init
SVB Leerink Maintains Outperform on Beam Therapeutics, Raises Price Target to $121
SVB Leerink analyst Rick Bienkowski maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $118 to $121.